Driver gene alterations profiling of Chinese non‐small cell lung cancer and the effects of co‐occurring alterations on immunotherapy. (2nd October 2021)

• Record Type: Journal Article
• Authors: Sun, Shengjie; Du, Wenjuan; Sun, Qiong; Zhao, Xiao; Qin, Boyu; Shi, Duozhi; Wan, Chong; Wu, Zhiyong
• Is Part Of: Cancer medicine. Volume 10:Number 20(2021)
• Page Start: 7360
• Page End: 7372
• Publication Date: 2021-10-02
• Subjects: co‐occurring -- driver genes -- EGFR -- immunotherapy -- non‐small cell lung cancer -- somatic alterations; 616.994005
• DOI: 10.1002/cam4.4178
• Languages: English
• ISSNs: 2045-7634

Abstract

Abstract: Background: Molecular testing for alterations in oncogenic driver genes and targeted therapies have become standard procedures for non‐small cell lung cancer (NSCLC) patients. However, little evidence has shed light on the pattern of co‐existence of driver genes in NSCLC, and whether they may have different tumor features affecting immunotherapy is still unclarified. Methods: Genomic alterations in 14 lung cancer‐related genes were conducted in 3440 Chinese NSCLC patients using next‐generation sequencing. Meanwhile, tumor mutational burden and immunotherapy dataset from the Memorial sloan kettering cancer center (MSKCC) and lung adenocarcinoma dataset from The Cancer Genome Atlas (TCGA) were utilized for analyzing the impact of the co‐occurring alterations on patients' survival following immunotherapy. Results: In this cohort, 90.17% of patients had at least one somatic alteration in the 14 genes, including 51% of co‐occurring alterations. TP53 and epidermal growth factor receptor (EGFR) were the most prevalent genes (54.74% and 53.55%, respectively), followed by KRAS, ERBB2, ALK, PIK3CA, ROS1, RET, MET, BRAF, KIT, FGFR1, PDGFRA, and NRAS . The prevalence of TP53, EGFR, and ERBB2 in our cohort were significantly higher than that from the TCGA database, whereas KRAS, BRAF, and PDGFRA were significantly lower than the latter. Furthermore, the patients who harbored multiple alterations (8.86%, 31/350) in eight driver genes survived longer and have a higher tumor mutation burden compared to the patients with a single alteration. Similar result was found between the patients with co‐occurring alteration of EGFR and other driver genes and the patients with single EGFR alteration. Meanwhile, we found a distinct immune cell infiltration feature between patients with single and multiple driver gene alterations, as well as between patients with only EGFR alteration and co‐occurring groups. Conclusion: This study identified a unique driver gene feature and found patients harboring co‐occurring alterations of EGFR and other driver genes may benefit from immunotherapy, which may provide more therapeutic selections for EGFR‐mutated NSCLC patients and merit additional investigation. Abstract : This study identified a unique driver gene feature and found patients harboring co‐occurring alterations of epidermal growth factor receptor (EGFR) and other driver genes may benefit from immunotherapy, which may provide more therapeutic selections for EGFR‐mutated non‐small cell lung cancer patients and merit additional investigation.